3Henk H J, Kaura S. Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in womenwith breast cancer and bone metastasis in a managed care plan[J]. J Med Econ, 2012, 15( 1 ):175. 被引量：1
4Henk H J, Kaura S. Assessment of zoledronic id treatment pat- terns and clinical outcomes in patients with bone metastases from genitourinary cancers[J]. J Med Econ, 2012,15( 1 ):185. 被引量：1
5Mountzios G, Ramfidis V, Terpos E, et al. Prognostic significance of bone markers in patients with lung cancer metastatic to the skele- ton: a review of published data [J]. Clin Lung Cancer, 2011,12 ( 6 ): 341. 被引量：1
6Santini D, Tampellini M, Vincenzi B, et al. Natural history of bone metastasis in eoloreetal cancer: final results of a large Italian bone metastases study[J]. Ann Oncol, 2012, [Epub ahead of print]. 被引量：1
7Coleman R E, McCloskey E V. Bisphosphonates in oncology [J], Bone, 2011, 49( 1 ): 71. 被引量：1
8Bourgeois D J 3rd, Kraus S, Maaloof B N, et al. Radiation for bone metastases[J]. Curt Opin Support Palliat Care, 2011, 5 (3): 227. 被引量：1
9Storto G, Klain M, Paone G, et al. Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases[J]. Bone, 2006, 39( 1 ):35. 被引量：1
10Robinson R G, Preston D F, Schiefelbein M, et al. Strontium 89 therapy for the palliation of pain due to osseous metastases[J]. JAMA, 1995, 274( 5 ) :420. 被引量：1
